What is the 13F Pro Quality Score for APYX?

13F Pro ranks Apyx Medical Corp (APYX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View APYX's current score at https://13fpro.ai/research/APYX (free sign-up required for the full ranking).

Where does 13F Pro source APYX data?

All Apyx Medical Corp fundamentals and ownership data come directly from SEC EDGAR. Apyx Medical Corp files with the SEC under CIK 719135. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is APYX in?

Apyx Medical Corp (APYX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is APYX research updated on 13F Pro?

APYX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Apyx Medical Corp(APYX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 719135 APYX stock profile & AI dashboard →

13F Pro Quality Score

19.3/100

Rank #2,697 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

26.6/100

Profitability

16.3/100

Balance Sheet

12.5/100

Earnings Quality

30.0/100

Free Cash Flow

16.1/100

Institutional Flow

37.4/100

Revenue Scale

10.3/100

Dilution Risk

30.0/100

APYX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Apyx Medical Corp (APYX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores APYX at 19.3/100 on a 32-signal composite quality model, placing it at rank #2,697 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (10.3) and balance sheet strength (12.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 30.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Apyx Medical Corp reports quarterly revenue of $12.5M, net income of $-2.1M, an operating margin of -7.3%. Top institutional holders of APYX by reported 13-F value include Nantahala Capital Management,, Archon Capital Management, ROYCE & ASSOCIATES, based on the most recent SEC filings. APYX trades on the Nasdaq exchange and files with the SEC under CIK 719135. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate APYX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Apyx Medical Corp directly from SEC EDGAR. Apyx Medical Corp's 13F Pro composite quality score has ranged between 15 and 29 since 2021, currently 19.3 — a declining long-term trajectory across 30 quarterly and live scoring snapshots.

Revenue

Q1 2026

$12.5M

Net Income

Q1 2026

$-2.1M

Free Cash Flow

Q1 2026

$-632.0K

Operating Margin

Q1 2026

-7.3%

D/E Ratio

Q1 2026

2.92

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+17.6% YoY

$52.3MFY 2023

FY20 $27.7MFY21 $48.5MFY22 $44.5MFY23 $52.3M

Net Income

+19.3% YoY

$-18.7MFY 2023

FY20 $-11.9MFY21 $-15.2MFY22 $-23.2MFY23 $-18.7M

Operating Income

+26.9% YoY

$-17.3MFY 2023

FY20 $-20.1MFY21 $-14.4MFY22 $-23.6MFY23 $-17.3M

EPS (Diluted)

+19.4% YoY

$-0.54FY 2023

FY20 $-0.35FY21 $-0.44FY22 $-0.67FY23 $-0.54

Total Assets

+53.0% YoY

$79.2MFY 2023

FY20 $74.1MFY21 $68.7MFY22 $51.8MFY23 $79.2M

Total Debt

$33.2MFY 2023

FY20 —FY21 —FY22 $0.00FY23 $33.2M

Op. Cash Flow

+74.1% YoY

$-5.2MFY 2023

FY20 $-16.1MFY21 $-10.4MFY22 $-20.3MFY23 $-5.2M

Metric	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2017
Revenue	$52.3M +17.6%	$44.5M -8.3%	$48.5M +75.1%	$27.7M -1.9%	$28.2M +175.9%	$10.2M
Net Income	$-18.7M +19.3%	$-23.2M -52.8%	$-15.2M -27.5%	$-11.9M +39.6%	$-19.7M -289.3%	$-5.1M
Operating Income	$-17.3M +26.9%	$-23.6M -63.3%	$-14.4M +28.1%	$-20.1M +3.8%	$-20.9M -50.3%	$-13.9M
EPS (Diluted)	$-0.54 +19.4%	$-0.67 -52.3%	$-0.44 -25.7%	$-0.35 +39.7%	$-0.58 -241.2%	$-0.17
Total Assets	$79.2M +53.0%	$51.8M -24.7%	$68.7M -7.3%	$74.1M -12.5%	$84.7M +173.5%	$31.0M
Total Debt	$33.2M	$0.00	—	—	—	$2.9M
Operating Cash Flow	$-5.2M +74.1%	$-20.3M -94.1%	$-10.4M +35.0%	$-16.1M +13.0%	$-18.5M -398.8%	$-3.7M

AI Insight: APYX Financial Trends

Losses are narrowing sharply — net loss compressed from $7M in Q2 2024 to $1M in Q4 2025 — but equity erosion and flat debt signal the runway is tightening.

• Net loss improved from $7M in Q2 2024 to $1M in Q4 2025, the best result in the observed period.

• Operating loss narrowed from $6M in Q2 2024 to breakeven $0M in Q4 2025, suggesting improving cost discipline.

• Revenue reached $19M in Q4 2025, up from $9M in Q1 2025, though Q1 2026 pulled back to $12M.

• Equity has declined from $15M in Q2 2024 to $13M in Q1 2026, eroded by sustained net losses over eight quarters.

⚠ Total debt has been flat at $38M since Q3 2024 while equity sits at $13M — leverage ratio remains elevated.

⚠ Operating cash flow has been negative every quarter; Q3 2025 saw a reversal to $4M outflow after two quarters of improvement.

⚠ Q1 2026 revenue of $12M and net loss of $2M represent a step back from Q4 2025 — monitor whether Q4 strength was seasonal.

AI Insight: APYX Ratio Trends

Apyx Medical turned briefly operating-profitable in Q4 2025 — its first positive operating margin in the dataset — but Q1 2026 slipped back to -7.3%, signaling a fragile, uneven recovery.

• Operating margin improved dramatically from -45.7% in Q2 2024 to +0.1% in Q4 2025, a ~46pp swing over six quarters.

• Net profit margin narrowed from -54.0% in Q2 2024 to -6.8% in Q4 2025, though Q1 2026 widened back to -16.9%.

• D/E ratio surged from 2.28 in Q2 2024 to 6.41 in Q3 2025 before falling sharply to 2.58 in Q4 2025, indicating volatile leverage.

• ROA improved from -40.1% in Q2 2024 to -7.8% in Q4 2025, but reversed to -13.4% in Q1 2026.

⚠ Q1 2026 operating margin retreated to -7.3% after Q4 2025's near-breakeven +0.1% — sustainability of profitability remains unproven.

⚠ D/E spiked to 6.41 in Q3 2025; though it eased to 2.92 in Q1 2026, leverage trajectory warrants close monitoring.

⚠ ROIC turned positive at +0.1% in Q4 2025 — first in the dataset — but slipped back to -7.2% in Q1 2026.

Get alerted when APYX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Apyx Medical Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of APYX

Nantahala Capital Management, LLC
$12.7M3,440,304 sh
Archon Capital Management LLC
$10.3M2,790,923 sh
ROYCE & ASSOCIATES LP
$9.6M2,611,224 sh
VANGUARD CAPITAL MANAGEMENT LLC
$5.7M1,555,272 sh
AIGH Capital Management LLC
$4.1M1,104,970 sh
Silverberg Bernstein Capital Management LLC
$3.8M1,041,070 sh
ESSEX INVESTMENT MANAGEMENT CO LLC
$3.3M901,398 sh
COMMONWEALTH EQUITY SERVICES, LLC
$2.4M649,061 sh
HORIZON KINETICS ASSET MANAGEMENT LLC
$2.3M615,000 sh
SEI INVESTMENTS CO
$2.2M598,255 sh

Fund	Value	Shares
Nantahala Capital Management, LLC	$12.7M	3,440,304
Archon Capital Management LLC	$10.3M	2,790,923
ROYCE & ASSOCIATES LP	$9.6M	2,611,224
VANGUARD CAPITAL MANAGEMENT LLC	$5.7M	1,555,272
AIGH Capital Management LLC	$4.1M	1,104,970
Silverberg Bernstein Capital Management LLC	$3.8M	1,041,070
ESSEX INVESTMENT MANAGEMENT CO LLC	$3.3M	901,398
COMMONWEALTH EQUITY SERVICES, LLC	$2.4M	649,061
HORIZON KINETICS ASSET MANAGEMENT LLC	$2.3M	615,000
SEI INVESTMENTS CO	$2.2M	598,255

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put APYX on your watchlist

Track score changes the day Apyx Medical Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is APYX a good stock to buy?

13F Pro's AI-powered analysis of Apyx Medical Corp (APYX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for APYX are available on the APYX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own APYX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling APYX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Apyx Medical Corp's investment landscape.